Logo image of HILS

HILLSTREAM BIOPHARMA INC (HILS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:HILS - US4327051011 - Common Stock

0.2305 USD
+0.01 (+2.76%)
Last: 9/22/2023, 8:03:56 PM
0.2308 USD
+0 (+0.13%)
After Hours: 9/22/2023, 8:03:56 PM
Fundamental Rating

2

Taking everything into account, HILS scores 2 out of 10 in our fundamental rating. HILS was compared to 530 industry peers in the Biotechnology industry. The financial health of HILS is average, but there are quite some concerns on its profitability. HILS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HILS had negative earnings in the past year.
HILS had a negative operating cash flow in the past year.
HILS Yearly Net Income VS EBIT VS OCF VS FCFHILS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -2M -4M -6M -8M

1.2 Ratios

The profitability ratios for HILS are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HILS Yearly ROA, ROE, ROICHILS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HILS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HILS Yearly Profit, Operating, Gross MarginsHILS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for HILS has been increased compared to 1 year ago.
HILS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HILS Yearly Shares OutstandingHILS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2M 4M 6M 8M 10M
HILS Yearly Total Debt VS Total AssetsHILS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -10.33, we must say that HILS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of HILS (-10.33) is worse than 80.46% of its industry peers.
There is no outstanding debt for HILS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.33
ROIC/WACCN/A
WACCN/A
HILS Yearly LT Debt VS Equity VS FCFHILS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 2M -2M 4M -4M -6M

2.3 Liquidity

A Current Ratio of 3.01 indicates that HILS has no problem at all paying its short term obligations.
With a Current ratio value of 3.01, HILS is not doing good in the industry: 71.19% of the companies in the same industry are doing better.
A Quick Ratio of 3.01 indicates that HILS has no problem at all paying its short term obligations.
With a Quick ratio value of 3.01, HILS is not doing good in the industry: 69.54% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.01
Quick Ratio 3.01
HILS Yearly Current Assets VS Current LiabilitesHILS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for HILS have decreased strongly by -160.68% in the last year.
EPS 1Y (TTM)-160.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

HILS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.99% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y35.9%
EPS Next 2Y34.45%
EPS Next 3Y23.24%
EPS Next 5Y2.99%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HILS Yearly EPS VS EstimatesHILS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

HILS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HILS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HILS Price Earnings VS Forward Price EarningsHILS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HILS Per share dataHILS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as HILS's earnings are expected to grow with 23.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.45%
EPS Next 3Y23.24%

More info and screens

0

5. Dividend

5.1 Amount

HILS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HILLSTREAM BIOPHARMA INC

NASDAQ:HILS (9/22/2023, 8:03:56 PM)

After market: 0.2308 +0 (+0.13%)

0.2305

+0.01 (+2.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2023-08-11/amc
Earnings (Next)11-06 2023-11-06
Inst Owners0.13%
Inst Owner Change-98.61%
Ins Owners19.51%
Ins Owner Change0%
Market Cap3.88M
Revenue(TTM)N/A
Net Income(TTM)-8.92M
Analysts43.33
Price Target4.08 (1670.07%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-51.52%
Min EPS beat(2)-104.99%
Max EPS beat(2)1.96%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.26
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.01
Quick Ratio 3.01
Altman-Z -10.33
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-160.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.09%
EPS Next Y35.9%
EPS Next 2Y34.45%
EPS Next 3Y23.24%
EPS Next 5Y2.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-147.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-465.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-465.08%
OCF growth 3YN/A
OCF growth 5YN/A

HILLSTREAM BIOPHARMA INC / HILS FAQ

What is the ChartMill fundamental rating of HILLSTREAM BIOPHARMA INC (HILS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to HILS.


Can you provide the valuation status for HILLSTREAM BIOPHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to HILLSTREAM BIOPHARMA INC (HILS). This can be considered as Overvalued.


What is the profitability of HILS stock?

HILLSTREAM BIOPHARMA INC (HILS) has a profitability rating of 0 / 10.


How financially healthy is HILLSTREAM BIOPHARMA INC?

The financial health rating of HILLSTREAM BIOPHARMA INC (HILS) is 5 / 10.


What is the earnings growth outlook for HILLSTREAM BIOPHARMA INC?

The Earnings per Share (EPS) of HILLSTREAM BIOPHARMA INC (HILS) is expected to grow by 35.9% in the next year.